Comparative Pharmacology
Head-to-head clinical analysis: DANTRIUM versus METAXALONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DANTRIUM versus METAXALONE.
DANTRIUM vs METAXALONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dantrolene inhibits calcium release from the sarcoplasmic reticulum by binding to the ryanodine receptor (RyR1), thereby reducing intracellular calcium concentration and decreasing muscle contraction.
Metaxalone is a centrally acting muscle relaxant whose exact mechanism is unknown. It is thought to produce skeletal muscle relaxation by depressing the central nervous system (CNS), possibly through general CNS depression or by blocking polysynaptic reflexes in the spinal cord.
Initially 25 mg orally once daily for 7 days, then 25 mg three times daily for 7 days, then 50 mg three times daily for 7 days, then 100 mg three times daily; maximum 400 mg/day in divided doses. For malignant hyperthermia crisis: IV bolus 1 mg/kg, repeated as needed up to 10 mg/kg cumulative dose.
800 mg orally 3 to 4 times daily
None Documented
None Documented
Clinical Note
moderateMetaxalone + Venlafaxine
"The risk or severity of adverse effects can be increased when Metaxalone is combined with Venlafaxine."
Clinical Note
moderateMetaxalone + Nefazodone
"The risk or severity of adverse effects can be increased when Metaxalone is combined with Nefazodone."
Clinical Note
moderateMetaxalone + Stiripentol
"The risk or severity of adverse effects can be increased when Metaxalone is combined with Stiripentol."
Clinical Note
moderateMetaxalone + Clomipramine
Terminal elimination half-life: 8.7-14.4 hours in adults; longer with hepatic dysfunction.
Terminal elimination half-life is approximately 0.5 to 1.5 hours, reflecting rapid clearance and supporting short-lived clinical effects.
Renal: ~65% as unchanged drug; biliary/fecal: ~15% as metabolites; remainder metabolized and eliminated via urine.
Primarily renal; approximately 90% of a dose is excreted in urine as glucuronide conjugates and unchanged drug, with less than 1% eliminated in feces via biliary excretion.
Category C
Category A/B
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant
"The risk or severity of adverse effects can be increased when Metaxalone is combined with Clomipramine."